

## COUNTRY GENERAL INFORMATION

Total population:	1,433,783,692
Gender F/M (%):	48.7 / 51.3
Population, age group <15 / ≥ 15 years (%):	18 / 82
Life expectancy at birth (F/M, years):	80 / 75
GDP (PPP int \$):	16,804
Income status:	Upper middle income
Number of 1 <sup>st</sup> sub-national administrative level divisions, name:	34, Province



## EPIDEMIOLOGY

	VL	CL	PKDL	MCL
Endemicity status:	Endemic	Endemic	Non endemic	Non endemic
Number of new cases (incidence):	166	3	N/A	N/A
Number of relapses: <sup>1</sup>	1	No data	N/A	N/A
<b>Total number of cases:</b>	<b>167</b>	<b>3</b>	<b>N/A</b>	<b>N/A</b>
Imported cases (#, %):	0, 0%	3, 100%	N/A	N/A
Gender distribution (% F):	31	No data	N/A	N/A
Age group distribution (% , <5 / 5-14 / >14): <sup>2</sup>	No data / 8 / 92	0 / 0 / 100	N/A	N/A
Incidence rate (cases/10,000 population in endemic areas):	No data	No data	N/A	N/A
Number of endemic 1 <sup>st</sup> sub-national administrative level divisions:	No data	No data	N/A	N/A
Population at risk (% , # at risk / total population): <sup>3</sup>	0% 0 / 1,433,783,692	0% 0 / 1,433,783,692	N/A	N/A
Was there any outbreak?	No	No data	N/A	N/A
Number of new foci: <sup>4</sup>	No data	3	N/A	N/A



## Monthly distribution of new cases (January-December)

2019	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	13	9	17	17	10	15	16	16	25	7	7	11

N/A not applicable; VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL = post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis



## Number of new cases and Incidence rate/10,000 at the national level from 2004 to 2019




<sup>1</sup>Relapse in this country is defined for VL as: "Any reappearance of VL symptoms within a period of 6 months after the end of treatment" and for CL as: "Parasites are still present in lesions that have healed 12 months after starting treatment"

<sup>2</sup>VL missing data. 44 patients out of 167 don't have their age defined among "less than 5 years old" and "unknown"

<sup>3</sup>Defined as "In this reporting period, an area at the 1st sub-national administrative level reporting cases for the first time ever"

<sup>4</sup>Defined as "Number of people living in 1st sub-national administrative level endemic areas"

## Disease distribution of new VL and CL cases at district level per 10,000 population (2019)



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.  
Map production: WHO/UCN/NTD

## CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	1950s
Type of surveillance (CL / VL):	Other / Other
Is there a vector control programme?	Yes
Type of insecticide used for Indoor residual Spraying (IRS):	Deltamethrin and lambda-cyhalothrin
Year latest national guidelines (CL / VL):	2006 / 2006
Is leishmaniasis notifiable (mandatory report)? (CL / VL):	Yes / Yes
Is there a reservoir host control programme?	No
Number of leishmaniasis health facilities (CL / VL):	No data / No data

## DIAGNOSIS

	VL	CL	PKDL	MCL
Number of people screened actively for:	No data	No data	N/A	N/A
Number of people screened passively for:	No data	3	N/A	N/A
VL cases diagnosed by RDT (% , # RDT+ / new VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT (% , # RDT+ / total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides + / total cases):	No data	No data	N/A	N/A
Proportion of positive slides (% , # slides + / total slides):	No data	No data	N/A	N/A
Cases diagnosed clinically (% , # clinical cases / total cases):	No data	N/A	N/A	N/A
Percentage of cases with HIV-VL coinfection:	No data	N/A	N/A	N/A

N/A not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

## TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? (CL / VL): Yes / Yes
- ▶ Antileishmanial medicines included in the National Medicine List: Sodium stibogluconate (SSG)

## INITIAL TREATMENT OUTCOME FOR NEW CASES

	VL	CL
Cases that completed treatment (% , # completed treatment / new cases):	No data	No data
Initial cure rate (% , # cases initially cured / new cases):	101% (167/166)	No data
Failure rate (% , # cases with treatment failure / new cases): <sup>5</sup>	No data	No data
Case fatality rate (% , # cases who died / new cases):	No data	No data

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL = post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis

<sup>5</sup>Failure in this country is defined as: "Signs and symptoms of VL/CL persist or recur after the end of treatment"